News Search Results
Sep 15, 2025, 09:00 ET MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
NEEDHAM, Mass., Sept. 15, 2025 /PRNewswire/ -- MLAB Biosciences, a biotechnology company pioneering novel therapies for neuromuscular disease, today announced the appointment of Edward M. Kaye,
More news about: MLAB Biosciences
Sep 15, 2025, 08:00 ET Matica Bio Secures Commercial Manufacturing Deal with U.S. Biotech Company
for complex CGT programs in a continuously evolving market governed by strict regulatory requirements." About Matica Biotechnology, Inc.Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at its purpose-built
More news about: Matica Biotechnology, Inc.
Sep 15, 2025, 08:00 ET Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced that Jonathan Kaufman, Chief
More news about: Lipella Pharmaceuticals Inc.
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
effective, durable, safer, and more manageable treatment options. About Argo Biopharma Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 15, 2025, 08:00 ET AuraVax Therapeutics Inc. receives grant for viral challenge study of new broad acting host-directed therapeutic
Joseph Sullivan, AuraVax's CEO. About AuraVax AuraVax Therapeutics, Inc. (AuraVax) is a privately held biotechnology company developing airway products based on our NanoSTING platform for the treatment and prevention of respiratory infections. NanoSTING activates
More news about: AuraVax Therapeutics Inc.
Sep 15, 2025, 07:30 ET Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms
abzena.com. About ProteoNicProteoNic is a privately held biotechnology company with offices in Leiden, The Netherlands. The company specializes in advanced cell line generation and viral
More news about: Abzena
Sep 15, 2025, 07:00 ET New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101
More news about: Kodiak Sciences Inc.
Sep 15, 2025, 07:00 ET Former Leaders of Thorne HealthTech and Tempus Launch Brain Health and Wellness Company BEVIMI at Inaugural CG Well Summit
HealthTech, where he led the company through 15 years of expansion. Prior to that, he was a private investor who served on various healthcare and biotechnology company boards of directors, including Progenics Pharmaceuticals. Earlier in his career, Jacobson was a Partner and Co-Head of the Liquid Capital
More news about: BEVIMI
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Sept. 15, 2025 /PRNewswire/ -- Gyala Therapeutics, a biotechnology company developing next-generation immunotherapies for blood cancers, announced the publication of preclinical results demonstrating the efficacy
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Sept. 15, 2025 /PRNewswire/ -- Gyala Therapeutics, a biotechnology company developing next-generation immunotherapies for blood cancers, announced the publication of preclinical results demonstrating the efficacy
More news about: Gyala Therapeutics
Sep 15, 2025, 05:45 ET Renewable Chemicals Market Size & Share to Surpass USD 525.8 Billion by 2035, Growing at a CAGR 11.75% | Vantage Market Research
chemicals, driven by U.S. federal bioeconomy policies, rising consumer preference for eco-friendly products, and technological advancements in biotechnology. The U.S. dominates regional production, focusing on biofuels, renewable polymers, and green solvents, while Canada
More news about: Vantage Market Research
Sep 15, 2025, 01:41 ET Skanska signs additional contract for biotechnology facility in Charlottesville, USA, for USD 116M, about SEK 1.2 billion
additional contract with the University of Virginia for the construction of the Paul and Diane Manning Institute of Biotechnology at Fontaine Research Park in Charlottesville, Virginia. The additional contract is worth USD
More news about: Skanska
Sep 14, 2025, 20:00 ET Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its
More news about: Phrontline Biopharma
Sep 14, 2025, 20:00 ET Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
China, Sept. 14, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the
More news about: Lion TCR
Sep 13, 2025, 16:32 ET Mars Snacking y Unreasonable Group dan la bienvenida a catorce nuevas empresas a Unreasonable Food™
Debut Biotechnology: fermenta ingredientes de alto valor, incluidas alternativas de color natural, para reemplazar fuentes sintéticas o que no son sostenibles.
More news about: Mars
Sep 13, 2025, 16:22 ET Mars Snacking e o Unreasonable Group dão as boas-vindas a quatorze novos empreendimentos da Unreasonable Food™
Debut Biotechnology : fermentação de ingredientes de alto valor, incluindo alternativas de cor natural, para substituir fontes insustentáveis ou sintéticas.
More news about: Mars
Sep 13, 2025, 16:10 ET Mars Snacking y Unreasonable Group dan la bienvenida a catorce nuevas empresas a Unreasonable Food™
Debut Biotechnology: Fermentación de ingredientes de alto valor, incluyendo colorantes naturales alternativos, para reemplazar fuentes insostenibles o sintéticas.
More news about: Mars
Sep 13, 2025, 16:08 ET Mars SnackingとUnreasonable Group、Unreasonable Food™に14の新規ベンチャーを迎える
Debut Biotechnology: 天然の代替着色料を含む高付加価値原料を発酵させ、持続不可能または合成の原料を置き換えます。
More news about: Mars
Sep 13, 2025, 16:04 ET Mars Snacking et Unreasonable Group accueillent quatorze nouvelles entreprises au sein d'Unreasonable Food™
Debut Biotechnology : la fermentation d'ingrédients de grande valeur, y compris des colorants naturels, pour remplacer les sources non durables ou synthétiques.
More news about: Mars
Sep 13, 2025, 16:01 ET Mars Snacking und Unreasonable Group begrüßen vierzehn neue Unternehmen bei Unreasonable Food™
Debut Biotechnology: Fermentierung von hochwertigen Inhaltsstoffen, einschließlich natürlicher Farbalternativen, um nicht nachhaltige oder synthetische Quellen zu
More news about: Mars
Sep 13, 2025, 11:20 ET Radioligand Therapy (RLT) Market worth US$10.9 billion by 2035 with 13.2% CAGR | MarketsandMarkets™
driven by its advanced healthcare infrastructure, high adoption of innovative oncology treatments, and strong presence of leading pharmaceutical and biotechnology companies. The region benefits from early approvals of key radioligand therapies, including Lutetium-177-based products, and a well-established
More news about: MarketsandMarkets
Sep 13, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
[Click here for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The Company is developing, among other
More news about: Pomerantz LLP
Sep 12, 2025, 19:04 ET 마즈 스내킹과 언리즈너블 그룹, 언리즈너블 푸드™에 참여할 14개 신규 벤처기업 선발
데뷰 바이오테크놀로지(Debut Biotechnology): 지속 불가능하거나 합성 원료를 대체하기 위해 천연 색소 대체재 등 고부가가치 원료를 발효한다.
More news about: Mars
Sep 12, 2025, 17:33 ET The National Institute of Biomedical Research and Ridgeback Biotherapeutics Respond to 16th Ebola Outbreak in the Democratic Republic of Congo
About Ridgeback BiotherapeuticsHeadquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback developed Ebanga™ for the treatment of Ebola virus disease caused by Orthoebolavirus
More news about: Ridgeback Biotherapeutics LP
Sep 12, 2025, 17:30 ET Mars Snacking and Unreasonable Group Welcome Fourteen New Ventures to Unreasonable Food™
Debut Biotechnology: Fermenting high-value ingredients, including natural color alternatives, to replace unsustainable or synthetic sources.
More news about: Mars